KRAS and neoplasm: In the mentioned dataset, authors identified only 1.7% of STK11 mutated SCLCs; noteworthy, these tumours were enriched in both KRAS (3.3%) and KEAP1 (3%) mutations, negatively affecting patients’ survival.